Literature DB >> 22478987

Experience with extended infusion of piperacillin-tazobactam at a teaching hospital.

Rosemary Zvonar1, Salmaan Kanji.   

Abstract

Entities:  

Year:  2010        PMID： 22478987      PMCID： PMC2901789          DOI： 10.4212/cjhp.v63i3.925

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  4 in total

1.  Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.

Authors:  Thomas P Lodise; Ben Lomaestro; George L Drusano
Journal:  Clin Infect Dis       Date:  2007-01-02       Impact factor: 9.079

2.  First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.

Authors:  Jason A Roberts; Carl M J Kirkpatrick; Michael S Roberts; Andrew J Dalley; Jeffrey Lipman
Journal:  Int J Antimicrob Agents       Date:  2009-12-16       Impact factor: 5.283

3.  Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.

Authors:  Robert E Ariano; Anna Nyhlén; J Peter Donnelly; Daniel S Sitar; Godfrey K M Harding; Sheryl A Zelenitsky
Journal:  Ann Pharmacother       Date:  2004-12-14       Impact factor: 3.154

4.  Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?

Authors:  Aryun Kim; Christina A Sutherland; Joseph L Kuti; David P Nicolau
Journal:  Pharmacotherapy       Date:  2007-11       Impact factor: 4.705
  4 in total
  1 in total

1.  Should Prolonged Infusion of β-Lactams Become Standard of Practice?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2017 Mar-Apr
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.